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The development of new point-of-care coagulation assay devices is necessary due to the increasing number of patients requiring long-
term anticoagulation in addition to the desire for appropriate, targeted anticoagulant therapy and a more rapid response to optimization of 
treatment. However, the majority of point-of-care devices currently available for hemostasis testing rely on clot-based endpoints which 
are variable and unreliable and are limited to measuring only certain portions of the coagulation pathway. There is a need for the 
introduction of point-of-care devices that can execute a broader range of tests; for example, the diagnosis of factor-specific diseases, as 
well as more reliable assays of anticoagulant status, particularly in response to the emergence of new anticoagulant drugs. Here we 
present a novel fluorescence-based anti-Factor Xa (FXa) microfluidic assay device for monitoring the effect of anticoagulant therapy at 
the point-of-care. The device is a disposable, laminated polymer microfluidic strip fabricated from a combination of hydrophobic and 
hydrophilic cyclic polyolefins to allow reagent deposition as well as allowing effective capillary fill. An immobilized FXa fluorogenic 
substrate was allowed to interact with 10 µl of a plasma/anticoagulant/exogenous FXa mixture within the microfluidic strip in a time-
controlled manner. The activity of uncomplexed FXa was measured with excitation at 342 nm and emission at 440 nm. The device was 
capable of measuring unfractionated and low molecular weight heparins from 0 to 0.8 U/ml within 60 s (CV<10%). The device also 
correlated well with both chromogenic and fluorogenic plate-based assays. 
 
Introduction 
Arterial and venous thromboembolism remain two of the most 
frequent causes of morbidity and mortality worldwide.1 Blood 
clotting disorders such as these have long been treated using 
anticoagulant drugs such as warfarin and heparin, with newer, 
more predictable drugs such as factor Xa (FXa) and thrombin 
inhibitors now available. The administration of anticoagulant 
therapy is carefully monitored due to the potential adverse effects 
associated with over- or under-dosing. Traditional tests used for 
monitoring warfarin and heparin include clot-based assays such 
as the prothrombin time (PT) and activated partial thromboplastin 
time (aPTT) tests.2 These assays were traditionally executed in 
the central diagnostic laboratory on automated coagulation 
analysers, but have since been adapted to small, benchtop 
analysers, as well as handheld monitors for use at the point-of-
care. Examples of such devices include the HemoSense INRatio 
monitor (Hemosense Inc., USA) for PT/INR home-testing, as 
well as the i-STAT (Abbott, USA) and Hemochron® analysers 
(ITC, USA) that can execute a range of clotting assays at the 
bench or bedside such as the PT, aPTT or ACT (activate clotting 
time). 
 Traditional anticoagulant drugs such as heparin have proven 
extremely effective. However, unfractionated heparin (UFH) is 
derived from animal sources such as porcine intestine and is 
highly variable in its molecular weight.3 This has unpredictable 
effects in its anticoagulant properties and so it must be closely 
monitored using clot-based assays such as aPTT and ACT.4,5 
New anticoagulant drugs such as low molecular weight heparins 
(LMWHs) have defined pharmacokinetics and 
pharmacodynamics. Such drugs preferably target FXa rather than 
thrombin (FIIa) in the coagulation cascade, but traditional 
clotting assays are based on the measurement of thrombin 
formation and are not suitable for monitoring these new drugs. 
Other assays such as the anti-Factor Xa (anti-FXa) assay have 
been developed to measure the effect of such drugs. The anti-FXa 
assay operates via the addition of exogenous FXa to a plasma 
sample from a patient treated with an anticoagulant drug. Plasma 
contains antithrombin (AT) which binds to coagulation factors 
such as thrombin and FXa, so inhibiting their procoagulant 
function.6 However, anticoagulant drugs such as heparin bind to 
AT and significantly increase binding affinity for both thrombin 
and FXa.2 In addition, the high molecular weight of UFH 
stabilizes a ternary complex of AT, thrombin and heparin. Thus, 
in the presence of these anticoagulant drugs, the availability of 
free thrombin and FXa is significantly reduced in a dose-
dependent manner, with a significant impact on thrombin 
generation. However, the LMWHs do not form stable ternary 
structures with AT and thrombin and so their antithrombin 
activity is substantially reduced, while their anti-FXa activity 
remains significant.7 Having been complexed with AT and 
anticoagulant drug, the concentration of free FXa is reduced and 
this can be titrated using a suitable substrate which is selectively 
cleaved by the serine protease activity of FXa. Pentapeptide 
substrates with chromophores for colorimetric assays are in 
widespread use.8,2 Unfortunately, absorbance-based assays are 
more prone to interference from blood and plasma. Recently, 
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fluorogenic substrates have been employed as fluorescent labels 
which are inherently more sensitive than colorimetric substrates, 
making these suitable labels in miniaturized diagnostic 
devices.9,10  
 While clot-based assays for PT, aPTT and ACT have been 
developed for the point-of-care, no such devices exist for the 
performance of anti-FXa assays. With the increasing use of 
LMWHs, as well as the development of other drugs such as direct 
anti-Xa inhibitors (e.g Rivaroxaban and Apixaban), the demand 
for such screening assays will increase. In addition, there is a 
major push for the screening of all individuals presenting upon 
emergency to be screened for their thrombotic risk profile, which 
is driving demand for development of point-of-care technologies 
in this area.11,12 
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 Current advances in point-of-care devices are often the result 
of microfluidic and microsystems technologies which aim to 
deliver rapid results, enhanced sensitivity and specificity on low-
cost, portable miniaturized devices.13,14 The development of a 
microfluidic device that uses optical detection such as 
fluorescence or absorbance requires the careful selection of 
device substrate materials. Glass has always been favored for 
optical applications due to its excellent clarity. However, its 
brittle nature results in processing and handling difficulties.15 
Other inorganic materials such as silicon and quartz are not ideal 
for disposable microfluidics due to high material and 
manufacturing costs.16 The use of polymer-based microfluidics 
has gained in popularity over the last few years with substrates 
such as cyclic polyolefins (COPs) becoming more widely used in 
microfabrication. COPs offer many advantages for application to 
point-of-care devices such as low autofluorescence, high UV 
transmission, high temperature resistance and chemical 
inertness.16,17 In addition COPs can be modified to create 
hydrophilic surfaces from their native hydrophobic state which 
aids in fluid flow and control, without the incorporation of 
complex pumping systems, which is an important parameter in 
the design of point-of-care devices. 
 A fluorogenic anti-FXa assay was previously developed in our 
laboratory for monitoring heparin therapy in both human 
calibration plasmas and patient plasmas.9,18 In this paper we 
present a miniaturized, disposable device incorporating the 
fluorogenic anti-FXa assay. Data is presented showing that it can 
be used effectively to monitor heparin anticoagulation (UFH, 
enoxaparin and tinzaparin) in plasma samples, hence its 
suitability for application to point-of-care testing. 
Experimental 
Reagents 
Water (ACS reagent) and HEPES (minimum 99.5% titration) 
were purchased from Sigma-Aldrich (Dublin, Ireland). Filtered 
HEPES was prepared at a concentration of 0.01 mM (pH 7.4). A 
100 mM filtered stock solution of CaCl2 from Fluka BioChemika 
(Buchs, Switzerland) was prepared from a 1 M CaCl2 solution.  
 The fluorogenic substrate methylsulfonyl-D-cyclohexylalanyl-
glycyl-arginine-7-amino-4-methylcoumarin acetate (Pefafluor™ 
FXa) was purchased from Pentapharm (Basel, Switzerland). It 
was reconstituted in 1 ml of water having a stock concentration of 
10 mM, aliquoted, covered with aluminum foil to protect from 
exposure to light, and stored at -20 °C. Dilutions from 10 mM 
stock solutions were freshly prepared with 0.01 mM HEPES 
when required. Purified human FXa (serine endopeptidase; code 
number: EC 3.4.21.6) was obtained from HYPHEN BioMed 
(Neuville-Sur-Oise, France) and was reconstituted in 500 µl of 
PCR grade water to give a stock concentration of 4400 nM, with 
subsequent dilutions made with 10mM HEPES buffer. 
Unfractionated heparin (UFH) (sodium salt of heparin derived 
from bovine intestinal mucosa, H0777) was sourced from Sigma-
Aldrich (Dublin, Ireland), Enoxaparin (Clexane®) and Tinzaparin 
(Innohep®) were obtained from Sanofi-Aventis (Paris, France) 
and LEO Pharma (Ballerup, Denmark) respectively. Human 
pooled plasma was purchased from Helena Biosciences Europe 
(Tyne and Wear, UK). Lyophilized plasma was reconstituted in 1 
ml of water and left to stabilise for at least 20 min at room 
temperature prior to use. 
 Rolls of 188 µm thick cyclic polyolefin polymer (Zeonor®) 
were purchased from IBIDI GmbH (Munich, Germany). 
ARcare® 92712 50 µm double sided pressure sensitive adhesive 
(PSA), BOPP-HY10 and HY10-coated Zeonor were purchased 
from Adhesives Research (Limerick, Ireland). Sheets of 188 µm 
Zeonor® was treated with a hydrophilic coating from Hydromer 
Inc. (NJ, USA). Strip materials were cut using a Graphtec Vinyl 
Cutter, Model CE5000-40-CRP from Graphtec GB Limited 
(Wrexham, UK). Contact angle measurements were carried out 
using an FTA 200 analyser from First Ten Angstroms, Inc. 
(Virginia, USA). 
 All fluorescent measurements were carried out at 37°C using 
an Olympus IX81 motorised fluorescent microscope sourced 
from Olympus Europa GmbH (Hamburg, Germany) housed 
within an incubation chamber with an attached Hamamatsu Orca 
ER digital camera, Model C4742-80-12AG  from Hamamatsu 
Photonics (Hertfordshire, UK). Fluorescence was monitored 
according to the following settings: magnification ×10; excitation 
at 342 nm and emission at 440 nm; exposure time of 20 ms. All 
values of fluorescence are reported as arbitrary fluorescence units 
(AU). All measurements were analyzed using the CellˆR realtime 
imaging software from Mason Technology (Dublin, Ireland) with 
subsequent data exportation into Excel, SigmaPlot 8.0, and SPSS 
17.0 for analysis. 
Microfluidic assay and device 
For final strip assembly, the hydrophobic Zeonor lid (75 mm x 25 
mm) was bonded to a PSA layer cut with a channel of 50 mm 
long x 2 mm wide, giving a total channel volume of 10 µl. The 
Zeonor lid was cut with an elliptical sample inlet of 4 mm 
diameter and a rectangular outlet of 4 x 1.5 mm to allow air to 
escape from inside the channel. 2 µl of Pefafluor™ FXa 
fluorogenic substrate was deposited with a pipette within the 
channel as four 0.5 µl droplets onto the hydrophobic Zeonor at a 
distance of 1.5 mm from the outlet (Fig. 1). Channels with 
deposited reagents were dried overnight in a glass desiccator with 
silica at 19°C and 10% RH. After drying, the strips were pressure 
laminated and sealed with a hydrophilic Zeonor base. 
 All measurements for the fluorogenic anti-FXa assay were 
carried out in reconstituted citrated human pooled plasma. 4 µl of 
260 nM FXa were incubated with 6 µl of re-calcified plasma (44 
µl heparinised plasma + 6 µl 100 mM CaCl2) for 10 seconds and 
 
10 µl of this FXa/plasma mixture was immediately applied to the 
inlet of the assay strip. Plasma samples were spiked with 
pharmacologically relevant concentrations (0–0.8 U/ml) of 
anticoagulants including UFH, enoxaparin, and tinzaparin, as 
appropriate.  
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 Detailed experimental protocols on the fluorogenic and 
chromogenic assay correlations can be found in the 
Supplementary Experimental Section S-1. 
 
Fig. 1. Schematic and photograph of the microfluidic anti-FXa assay 10 
device. Strips were assembled from a hydrophobic Zeonor lid containing 
an inlet and outlet. The single straight channel was cut from PSA which 
seals the lid and base layers. The base layer was hydrophilic zeonor to 
allow for capillary fill of the strip. Fluorogenic FXa substrate was 
deposited onto the hydrophobic lid prior to assembly. 15 
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Results and discussion 
While coagulation monitoring devices occupy a large portion of 
the point-of-care market, there is significant scope for the 
development and introduction of novel devices, which offer 
improvements over conventional clotting tests for anticoagulant 
monitoring. Peptide substrates specific for coagulation proteins 
such as thrombin and plasmin emerged in the 1960s19,20, with the 
first anti-Xa chromogenic assay for heparin monitoring 
developed in 1976.21 The chromogenic anti-FXa assay is now 
classed by central diagnostic laboratories as the ‘gold standard’ 
assay for measuring heparin anticoagulant therapy in plasma 
samples. However, point-of-care -based anti-Xa assay systems 
have yet to be developed. 
 
Strip materials characterization and selection 
 
For the development of point-of-care microfluidic assay devices, 
polymer-based materials are by far the most widely used due to 
the low cost of the materials, the range of simple fabrication 
methodologies available, their inert physical characteristics and 
good compatibility with biological materials. There are a range of 
popular polymer materials available such as polycarbonate (PC), 
polyethylene terephthalate (PET) and polymethylmethacrylate 
(PMMA).22,23 However, such materials do suffer from some 
disadvantages. For sensitive assays based on fluorescence 
detection, their high background fluorescence is a problem. An 
alternative group of polymers with low inherent fluorescence are 
the cyclic polyolefins. These are now finding widespread use in 
bioassays in which sensitive fluorescence-based methods are 
used. These polymers like many others suffer from significant 
hydrophobicity and so can be challenging when used with liquid 
biological samples such as blood where capillary flow is required. 
A range of surface treatments and modifications have been 
developed to improve the hydrophilicity of these materials and 
this has made them viable materials for biodevice development.23 
 A range of transparent polymer materials were initially 
screened for their background fluorescence characteristics when 
excited at 342 nm. These were PMMA, PET, Zeonor® and 
Topas, the latter two being cyclic olefin polymers. Among these, 
Zeonor® was found to have the lowest fluorescence (data not 
shown). However, the hydrophobicity of the Zeonor films was 
still problematic, preventing good capillary flow. A number of 
cyclic polyolefins with various hydrophilic surface coatings were 
analyzed for their auto-fluorescence properties, as well as their 
water contact angle measurements and capillary fill 
characteristics when assembled into a simple capillary channel 
(Fig. 2). While both of the HY10-modified films had excellent 
contact angles and capillary fill times (7.6° ± 0.7° and 23 ± 1s, 
respectively) the HY10 surface modification contributed 
significantly to the background fluorescence (640.9 ± 2.3 AU, 
where maximum fluorescence = 4000 AU). Unmodified Zeonor 
exhibited low fluorescence as is well established. However, it 
showed high contact angles in excess of 100° and capillary fill 
times were not recordable as liquid could not flow along the 
channel, making it unsuitable. The Hydromer-modified Zeonor 
exhibited comparable fluorescence with unmodified Zeonor of 
208.5 AU, as well as having excellent contact angles (17.5° ± 
0.9°) and capillary fill times (20.3 ± 2.1 s).  
 In circumstances where the deposition of small volumes of 
aqueous-based reagents is required onto such polymeric surfaces, 
hydrophilic surfaces result in the deposited material spreading in 
an unpredictable manner across the surface due to its good 
wetting properties. Thus, a hybrid hydrophobic/hydrophilic 
design was proposed which would possess a hydrophobic layer 
for reagent deposition and a hydrophilic layer to induce capillary 
flow. Devices assembled using this hybrid approach were 
composed of materials with fill times of 20.3 ± 2.1 s, contact 
angles of 17.5° ± 0.9° s and low background fluorescence levels 
of 208.5 ± 0.1 AU which were intermediate to either fully 
hydrophobic or fully hydrophilic devices. Thus, further device 
development was based on Zeonor and Zeonor modified with 
Hydromer coating. The final assay device configuration was a 
three layer laminate strip comprising a 188 µm thick hydrophilic 
Zeonor base to induce capillary flow, a 50 µm PSA spacer with 
channel and a 188 µm hydrophobic Zeonor lid for reagent 
deposition. 
 
 
 
 
 
 
 
 
  
Fig. 2. Evaluation of device materials in terms of their auto-fluorescence, 
capillary fill times in assembled strip, and water contact angles (n=3). 
 
Assay optimization 
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Using a plate-based fluorogenic anti-FXa assay as a guideline9, 
the assay was transferred to and optimized on the strip format. 
FXa and Pefafluor™ FXa fluorogenic substrate were titrated 
within the range of 60-460 nM and 30-180 µM, respectively. 
Initial titrations were performed on chip with FXa and 
Pefafluor™ FXa dried onto the Zeonor surface. Fig. 3 shows 
typical fluorescence response profiles of the strip to different 
concentrations of Pefafluor™ FXa substrate at a FXa 
concentration of 260 nM. This illustrates the conversion of 
fluorogenic substrate to fluorescent product which is limited by 
substrate concentration below 120 µM. After approx. 60 s, all 
substrate has been converted. It can also be observed that the 
maximum fluorescence signal that could be achieved with the 
available instrumentation was approximately 4000 AU which was 
achieved with substrate concentrations in excess of 60 µM. To 
ensure that substrate limitation did not result, a concentration of 
150 µM was selected. 
 
 
 
 
Fig. 3: Typical fluorescence profiles of the anti-Xa assay with 260 nM 
FXa and concentrations of Pefafluor™ FXa from 30 to 180 µM (n=3). 
 
  
Titrations of FXa concentration were performed, maintaining 
Pefafluor™ concentration at 150 µM and varying FXa 
concentration from 60 to 460 nM at 0, 0.5 and 1U/ml heparin 
(Fig. 4). The effect of heparin on the response of each titration 
was analyzed and regression analysis was used to determine the 
optimal concentration of FXa. Regression analysis for 60 and 120 
nM FXa returned R2 values of 0.99. However, a wider signal 
range and a higher value at 0 U/ml was achieved at 260 nM with 
an R2 value of 0.99. At higher concentrations of 360 nM and 460 
nM FXa, regression analysis returned lower R2 values of 0.93 and 
0.87, respectively. Final assay concentrations were thus 
optimized at 150 µM fluorogenic substrate and 260 nM FXa and 
were tested using heparinised plasma samples at 0.25 U/ml 
intervals from 0 to 0.8 U/ml. Good separation was observed 
between heparin concentrations. 
Another important feature of assay and device development 
was sample volume. The device required 10 µl of plasma to 
execute a measurement, which is in line with point-of-care 
devices such as the CoaguCheck (Roche Diagnostics, UK), yet 
significantly lower than the 50 µl sample volume required to 
perform a test on the Hemochron® systems or the 20 µl sample 
volume required for application to the i-STAT analysers (Abbott, 
USA).24 The fast turnaround time of 60 seconds is also a 
significant advantage of the anti-FXa fluorogenic point-of-care 
device. 
 
Fig. 4: Fluorescence responses at 60 s for 60 to 460 nM FXa and 150 µM 
fluorogenic substrate at 0, 0.5 and 1 U/ml UFH (n=3). 
 
Optimization of substrate deposition 
 
One of the most challenging aspects of the development of 
miniaturized diagnostic devices remains the effective deposition 
and subsequent resolubilisation of the assay reagents within the 
microfluidic device. Some aspects of this relate to the process 
used for deposition and others to the material being deposited. 
These factors can have a significant impact on assay performance 
and reproducibility. In the current assay device, four x 0.5 µl 
spots of the fluorogenic substrate were deposited in the 
microfluidic channel close to the measurement chamber. While 
automated methods of deposition are generally required for mass 
production to achieve control of volume and positional accuracy, 
it was found here that manual pipetting achieved reliable and 
reproducible results with spot diameters of 877 ± 51 µm with 
CVs of 6% (n=10), compared to inkjet printed spot diameters of 
1094 ± 155 µm with CVs of 14 % (n=10). 
 
 A range of buffers (10 mM HEPES, 0.01 mM HEPES, 
StabilCoat buffer, 2% Tween 20, 10% PEG 3400, 1% Triton X-
100) were tested for their effect on the dissolution, deposition and 
drying characteristics of the fluorogenic substrate. The 
morphology of the dried substrate spots can be seen in Fig. S-1 
(A-F). It can immediately be seen that the matrices based on 
HEPES, StabilCoat and PEG produced uniform spots. However, 
the mixtures containing surfactant showed spot spreading and 
irregularity. Both the 10 mM HEPES and StabilCoat buffers 
showed a classical coffee-ring or doughnut morphology due to 
the movement of material to the edge of the droplet during 
drying. The dried polymer could also be seen in the sample 
containing PEG. However, 0.01 mM HEPES buffer resulted in 
uniform spots with few defects. Horizontal spot diameters 
measured on average 845 µm ± 59 µm (n=10; CV = 6.9%) and 
vertical spot diameters measured 877 µm ± 51 µm (n=10; CV = 
5.8%). 
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 Based on these morphological characteristics and fluorescent 
assay responses, HEPES buffer was found to be the most suitable 
matrix for the fluorogenic substrate. The impact of HEPES 
concentration on the performance of the substrate was further 
assessed. Three concentrations of HEPES buffer were 
subsequently tested for optimal performance in the assay using 
plasma or plasma with 0.5 U/ml UFH, 260 nM FXa and 150 µM 
substrate in 0.01, 0.05, and 0.1 mM HEPES (Fig. S-2). HEPES at 
0.01 mM was selected as the optimal concentration as it returned 
the maximum fluorescence signal at 0 U/ml heparin and showed 
the greatest potential signal range with the smallest errors (1,896 
AU between 0 U/ml and 0.5 U/ml). 
 The effect of temperature on the drying of the fluorogenic 
substrate was also assessed. Fluorogenic substrate prepared in 
0.01 mM HEPES was dried onto the microfluidic devices using a 
range of temperature and humidity. The most reliable and 
reproducible method of drying as determined from the 
morphology of the deposited spots proved to be drying at room 
temperature, at 10% RH, in a glass desiccator, which was 
subsequently adopted for preparation of assay devices. 
 
Anticoagulant calibrations 
 
The fluorescence responses of the optimized assay configuration 
were tested over a range of UFH concentrations. Fig. S-3 
illustrates the typical fluorescent responses seen from the assay 
device (n=3). It can be seen that the fluorescence responses 
demonstrated inversely proportional dose-dependent rates of 
residual FXa enzymatic activity, with decreasing rates of product 
formation at higher drug concentrations, illustrating the anti-FXa 
activity of the AT/UFH complex formed. At lower drug 
concentrations, the responses appeared to show some deviation 
from linearity, with an initial upward trend, suggesting enzyme 
activity was increasing over this period. After approximately 43 s 
and 55 s, respectively, 0 and 0.2 U/ml heparin curves appeared to 
plateau. This is in part due to the reaching of the upper signal 
range achievable with the instrumental set up, but may also have 
a contribution from substrate limitation. Dosages above 0.6 U/ml 
had significantly titrated out all of the available FXa, with 1 U/ml 
showing little change over background levels. 
 Various methods can be employed to analyze the responses 
from these types of assays, including rates of change and 
responses at fixed time points. The log of the fluorescence 
responses at 30, 60 and 90 s were analyzed (Fig. 5 and Table S-
1). Fluorescence at 30 and 90 s returned R2 values of 0.99 and 
0.93, with slopes of -0.915 and -1.205, respectively. However, the 
regression at 60 s yielded an R2 of 0.97 and a slope of -1.12. 
Assay measurements performed at 60 s were shown to be capable 
of measuring UFH in the range of 0 to 0.8 U/ml with intra-assay 
CVs of <15% (n=3). 
 
Fig. 5: Linear regression analysis of fluorescent responses at 30, 60 and 
90 seconds. 
 
 Two LMWH anticoagulants (tinzaparin and enoxaparin) were 
also tested on the anti-FXa microfluidic device and were 
analyzed along with UFH (Fig. 6). Linear regression analysis 
with enoxaparin returned an R2 value of 0.98 with a linear 
correlation of y = -0.945 + 3.659, while analysis of tinzaparin 
yielded an R2 value of 0.96 with a linear correlation of y = -0.789 
+ 3.637. Statistical analysis was performed on the logarithmically 
transformed datasets to assess intra-assay variability. When tested 
with enoxaparin-spiked plasmas a statistically sensitive range of 0 
to 0.6 U/ml was achieved with CVs of <11%, while the limit of 
detection was 0.8 U/ml for plasma samples containing tinzaparin, 
with CVs of <12%. 
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Fig. 6: Dose-response curves of human plasma spiked with UFH, 
enoxaparin and tinzaparin in the microfluidic anti-FXa assay device 
(n=3).  
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For validation purposes, the microfluidic assay device was 
correlated with both a fluorogenic microtitre plate-based anti-FXa 
assay as previously described by Harris et al.9 and with the 
commercial Biophen® chromogenic assay from Hyphen BioMed 
(Neuville-Sur-Oise, France) (Fig. 7). A linear correlation was 
observed between the device and the fluorescent assay in the 
plate for plasma samples spiked with UFH, with an excellent R2 
value of 0.99 (Fig. 7A). However, correlations of the device and 
the fluorogenic plate-based assay with tinzaparin and enoxaparin 
(Fig. 7C, 7E) resulted in sigmoidal correlations (R2 = 0.99).  
 Correlations similar to that seen between with the fluorogenic 
plate-based assay were also observed with the chromogenic 
assay. UFH plasma samples again resulted in a linear correlation 
between the device and the chromogenic assay with an R2 value 
of 0.98 (Fig. 7B). For both LMWHs tested in the chromogenic 
assay, the correlations with the device also had a sigmoidal 
relationship (R2 = 0.99) (Fig. 7D, 7F). This indicates an increased 
sensitivity of the microfluidic assay device at intermediate 
LMWH concentrations compared to the standard assays. 
Although the reason for this is not clear, the linear correlations 
for UFH suggest a combination of both mechanistic factors 
relating to the pharmacokinetics of the drugs and their interplay 
with the kinetics of the microfluidic assay device. Nonetheless, 
correlations between the microfluidic device and both 
chromogenic and fluorogenic assays were achieved. 
 A point-of-care device based on the anti-Xa assay is not 
currently available so comparisons on levels of sensitivity and 
precision for this device can really only be drawn with clot-based 
devices for heparin measurement currently on the market. The 
aPTT is recommended for monitoring heparin therapy. However, 
there are serious limitations that accompany this assay in terms of 
the measurement range and the inter-laboratory variability.25 For 
example, clinically and statistically significant differences were 
observed between a point-of-care  aPTT assay and a laboratory-
based aPTT assay used to monitor patients on heparin therapy.26 
Despite its disadvantages, the aPTT remains the most reliable and 
readily available test for clinicians, who will continue to use it 
until the emergence of a more accurate diagnostic test. 
 While many analysers exist and have been researched in the 
literature, the Hemochron® systems are the most widely accepted 
and commonly used, particularly for the measurement of aPTT. 
The Hemochron® system for aPTT measurement reports linearity 
with heparin up to 1.5 U/ml, at intervals of 0.25 U/ml and CVs of 
<10%.27 The Cascade® aPTT system from Helena Biosciences 
reports linearity up to 0.5 U/ml with an R2 of 0.98, with intra and 
intervariability at <3% for normal and abnormal samples. A 
correlation of 0.72 with the anti-Xa chromogenic assay is also 
reported on the company datasheet.28 In the current study we 
observed linearity up to 0.8 U/ml with the anti-Xa device for 
UFH, enoxaparin and tinzaparin, with concentrations tapering off 
at 1 U/ml. 
 When the aPTT is compared to other clotting tests for heparin 
poor correlations are often observed, due to the variable 
responsiveness of commercial aPTT reagents to heparin.2  In 
terms of comparative studies, one research group compared 
bedside aPTT with laboratory aPTT using patients on heparin, 
with correlations varying from 0.13 to 0.67.29 Chavez et al.30 
compared the CoaguChek™ Pro DM with core laboratory 
facilities for CPB (cardiopulmonary bypass) patients that 
received heparin therapy prior to surgery and a linear correlation 
(R2 = 0.83) between the two assays was achieved. These findings 
were corroborated to a certain degree by Ferring et al.31 who 
reported poor agreement with patients after surgery but better 
agreement with healthy volunteer and control patient samples. In 
their study the anti-Xa assay also provided the best correlation 
with heparin dosage compared to point-of-care aPTT and central 
laboratory aPTT. In our study linear correlations (R2 of 0.99) 
between the device and both plate-based assays were observed 
with control plasma samples containing UFH. 
 The prothrombinase-induced clotting time assay (PiCT) is a 
point-of-care clotting time assay, sensitive to inhibitors of both 
thrombin and Xa. Calatzis et al.32 compared the PiCT with both 
aPTT and anti-Xa chromogenic assays for a range of 
anticoagulants. A non-linear response was observed with patients 
on fondaparinux, a synthetic inhibitor of FXa, while an almost 
linear response was achieved with patients on UFH, dalteparin, 
and enoxaparin. When comparing our device to the established 
chromogenic assay with samples spiked with LMWHs, we also 
observed non-linear correlations. However, using a sigmoidal 
treatment, excellent correlations of 0.99 were observed. This non-
linearity with LMWH has also been reported by Coppell et al.33 
who demonstrated a loss of linearity at LMWH concentrations 
above 0.5 U/ml when comparing TEG with a conventional aPTT 
clotting assay.  
 
  
Fig. 7: Correlations of the anti-Xa assay in the microfluidic device with the anti-FXa plate-based assay and the Biophen® chromogenic assay for UFH (a-
b), tinzaparin (c-d), and enoxaparin (e-f) (n=3).  
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The ability to measure the concentration of both unfractionated 
and low molecular weight heparin anticoagulant drugs in plasma 
was demonstrated using a polymer microfluidic device with 
integrated anti-FXa assay. Fluorescent measurement after 60 s 
demonstrated assay ranges from 0 to 0.6 U/mL for enoxaparin 
and 0 to 0.8 U/mL for UFH and tinzaparin. The assay platform 
was shown to correlate well against both chromogenic and 
fluorogenic anti-FXa assays performed in microtitre plates. Such 
a device could be used at the point-of care for monitoring anti-
coagulant therapies. 
 
 
 
Acknowledgements 
This work was supported by Enterprise Ireland under Grant No. 
TD/2009/0124. 
 
This journal is © The Royal Society of Chemistry [year] Journal Name, [year], [vol], 00–00  |  7 
 
Notes and references 
a Biomedical Diagnostics Ins
8  |  Journal Name, [year], [vol], 00–00 This journal is © The Royal Society of Chemistry [year] 
titute, National Centre for Sensor Research, 
5 
.uk 
Dublin City University, Dublin 9, Ireland. Tel: + 00 353 1 7006332; E-
mail: leanne.harris@dcu.ie 
b School of Mathematics and Physics, Queen’s University Belfast, Belfast, 
BT7 1NN, Northern Ireland, UK. E-mail: P.Rainey@ee.qub.ac
c CIC microGUNE, Microfluidics Unit, Polo Innovación Garaia, 20500 
Mondragón, Spain. E-mail: vanessa.castro.lopez@gmail.com 
d Haemostasis Research Group, Institute of Molecular Medicine, St 
10 
harbour Lane, Bristol, BS16, 1QY, UK. Fax: + 
0 44 1173442904; Tel: + 00 44 1173282147; E-mail: 
15 
 Electronic Supplementary Information (ESI) available: 
20 
25 
30 
35 
40 
45 
50 
50 µl of plasma and 50 µl of antithrombin (AT). To this, 50 µl of 
FXa was added. The reaction was started by adding 50 µl of FXa 
specific chromogenic substrate. Samples within wells were mixed 55 
within the spectrophotometer by orbital shaking at 37 ºC for 30 s. 
Immediately after shaking, absorbance measurements were 
recorded at 37 ºC for 60 min, at 10 s intervals. Absorbance was 
measured at 405 nm and all measurements were performed in 
triplicate. 60 
rate deposited in a range of 
buffers (x 100 magnification): (a) 10 mM HEPES buffer (b) 0.01 mM 
HEPES buffer (c) StabilCoat buffer (d) 2 % Tween 20 (e) 10 % PEG 
3400 (f) 1 % Triton X-100. 65 
 
S-2 Results and discussion 
Optimization of substrate deposition 
ig. S-2: Comparison of the fluorescence responses of unheparinised (0 
/ml) and heparinised (0.5 U/ml) plasmas in microfluidic devices with 70 
uorogenic substrate prepared in 0.1, 0.05, and 0.01 mM HEPES buffer 
=3). 
75 
80 
 
 
 85 
 
 
James’s Hospital, Trinity College, Dublin 8, Ireland. Tel: + 00 353 1 
4164844; E-mail: jodonne@tcd.ie 
eDepartment of Applied Sciences, University of the West of England, 
Frenchay Campus, Cold
0
tony.killard@uwe.ac.uk 
 
†
See DOI: 10.1039/b000000x/ 
 
S-1 Experimental section †
Fluorogenic and chromogenic assay correlations 
 
Absorbance and fluorescence measurements were performed in 
an Infinite M200 spectrophotometric microplate reader (Tecan 
Group Ltd, Männedorf, Switzerland) equipped with a UV Xenon 
flashlamp. Flat, black-bottom 96-well polystyrol FluorNunc™ 
microplates from Thermo Fisher Scientific (Roskilde, Denmark) 
were used for fluorescence measurements. Flat, transparent 96-
well Greiner® microplates from Greiner Bio-One 
(Gloucestershire, United Kingdom) were used for absorbance 
measurements. All measurements for the fluorogenic anti-FXa 
assay and the chromogenic assay were carried out in reconstituted 
citrated human pooled plasma. Pooled commercial plasma 
samples were spiked with pharmacologically relevant 
concentrations (0–0.8 U/ml) of therapeutic anticoagulants 
including UFH, enoxaparin, and tinzaparin.  
 For the fluorogenic assay, FXa and Pefafluor FXa fluorogenic 
substrate concentrations were previously optimized as 4 nM and 
0.9 µM, respectively.9 Each well contained 6 µl of 100 mM 
CaCl2, 44 µl of pooled plasma, and 50 µl of FXa. The reaction 
was started by adding 50 µl of Pefafluor FXa fluorogenic 
substrate. Samples within wells were mixed with the aid of 
orbital shaking at 37 °C for 30 s. Immediately after shaking, 
fluorescence measurements were recorded at 37 °C for 60 min, 
with a 20 µs integration time.  Fluorescence excitation was at 342 
nm and emission was monitored at 440 nm, corresponding to the 
excitation/emission wavelengths of the 7-amino-4-
methylcoumarin (AMC) fluorophore. All the measurements were 
carried out in triplicate.  
 The Biophen® Heparin chromogenic assay from Hyphen 
BioMed (Neuville-Sur-Oise, France) was carried out according to 
the manufacturer’s instructions as follows: each well contained 
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Fig. S-3: Fluorescence response profiles of human plasmas in the anti-
FXa assay de
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